Research graph
References from Risk of hyperprolactinemia and extrapyramidal symptoms in antipsychotic-treated schizophrenia: a retrospective single-center real-world study. Local targets link to admitted publications; unresolved targets remain external evidence.
Quetiapine is not associated with increase in prolactin secretion in contrast to haloperidol
10.1016/s0188-4409(02)00403-4 · 2002 · External reference
New insights in prolactin: pathological implications
10.1038/nrendo.2015.36 · 2015 · External reference
Antipsychotic-induced hyperprolactinemia
10.1592/phco.29.1.64 · 2009 · External reference
Estrogens in schizophrenia: progress, current challenges and opportunities
10.1097/yco.0000000000000699 · 2021 · External reference
Hyperprolactinemia and antipsychotics: it's not always what it seems to be
2021 · External reference
Relapse in patients with schizophrenia and amisulpride-induced hyperprolactinemia or olanzapine-induced metabolic disturbance after switching to other antipsychotics
10.1016/j.psychres.2023.115138 · 2023 · External reference
Hyperprolactinemia and bone
10.1007/s11102-020-01041-3 · 2020 · External reference
Atypical antipsychotics in the EPS-vulnerable patient
10.1016/s0306-4530(02)00111-7 · 2003 · External reference
Antipsychotic-induced hyperprolactinemia in aging populations: prevalence, implications, prevention and management
10.1016/j.pnpbp.2020.109941 · 2020 · External reference
The effect of menopause on antipsychotic response
10.3390/brainsci12101342 · 2022 · External reference
Adverse effects of atypical antipsychotics: differential risk and clinical implications
10.2165/00023210-200721110-00004 · 2007 · External reference
Overview of hyperprolactinemia: general approach and reproductive health implications
10.1016/j.arcmed.2024.103102 · 2024 · External reference
Hyperprolactinemia-inducing antipsychotics increase breast cancer risk by activating JAK-STAT5 in precancerous lesions
10.1186/s13058-018-0969-z · 2018 · External reference
In vivo 5-HT2A receptor blockade by quetiapine: an R91150 single photon emission tomography study
10.1007/s002130100761 · 2001 · External reference
Antipsychotics: mechanisms underlying clinical response and side-effects and novel treatment approaches based on pathophysiology
10.1016/j.neuropharm.2019.107704 · 2020 · External reference
Burden of EPS in commercial patients with schizophrenia initiating atypical antipsychotics
10.37765/ajmc.2022.89163 · 2022 · External reference
Risperidone-associated hyperprolactinemia. Endocrine practice
10.4158/ep.6.6.425 · 2000 · External reference
Switch to quetiapine in antipsychotic agent-related hyperprolactinemia
10.1007/s100720200047 · 2002 · External reference
Clinical research using real-world data: a narrative review
10.1016/j.resinv.2024.08.002 · 2024 · External reference
Efficacy, acceptability, and tolerability of antipsychotics in children and adolescents with schizophrenia: a network meta-analysis
10.1016/j.euroneuro.2018.03.008 · 2018 · External reference
Antipsychotic-related prolactin changes: a systematic review and dose-response meta-analysis
10.1007/s40263-025-01218-z · 2025 · External reference
Pharmacological treatment strategies for antipsychotic-induced hyperprolactinemia: a systematic review and network meta-analysis
10.1038/s41398-022-02027-4 · 2022 · External reference
Thyroid function assessment before and after diagnosis of schizophrenia: a community-based study
10.1016/j.psychres.2020.113356 · 2020 · External reference
Diagnosis and treatment of hyperprolactinemia: an endocrine society clinical practice guideline
10.1210/jc.2010-1692 · 2011 · External reference
Recent clinical aspects of hyperprolactinemia induced by antipsychotics
10.2174/157488711793980138 · 2011 · External reference
Hyperprolactinemia induced by antipsychotics: from diagnosis to treatment approach
10.2174/1871530317666170424102332 · 2017 · External reference
Paliperidone induced hypothyroidism: a case report
10.64719/pb.4527 · 2025 · External reference
Multidisciplinary consensus on the therapeutic recommendations for iatrogenic hyperprolactinemia secondary to antipsychotics
10.1016/j.yfrne.2017.02.003 · 2017 · External reference
Quetiapine-induced galactorrhea with normal prolactin level in an adult female patient
10.4088/pcc.11l01284 · 2012 · External reference
A safety evaluation of aripiprazole in the treatment of schizophrenia
10.1080/14740338.2020.1832990 · 2020 · External reference
Antipsychotics-induced hyperprolactinemia and screening for macroprolactin
10.11613/bm.2021.010707 · 2021 · External reference
Adjunctive treatment with a dopamine partial agonist, aripiprazole, for antipsychotic-induced hyperprolactinemia: a placebo-controlled trial
10.1176/appi.ajp.2007.06071075 · 2007 · External reference
Antipsychotic dose, dopamine D2 receptor occupancy and extrapyramidal side-effects: a systematic review and dose-response meta-analysis
10.1038/s41380-023-02203-y · 2023 · External reference
Real world big data for clinical research and drug development
10.1016/j.drudis.2017.12.002 · 2018 · External reference
Antipsychotic use and risk of low-energy fractures in people with schizophrenia: a nationwide nested case-control study in Finland
10.1093/schbul/sbac152 · 2023 · External reference
Current insights in Prolactin signaling and ovulatory function
10.3390/ijms25041976 · 2024 · External reference
Antipsychotic use and risk of breast cancer in women with schizophrenia: a nationwide nested case-control study in Finland
10.1016/s2215-0366(21)00241-8 · 2021 · External reference
Genome-wide association study identified six loci associated with adverse drug reactions to aripiprazole in schizophrenia patients
10.1038/s41537-023-00369-6 · 2023 · External reference
Dose-dependent effects of antipsychotics on efficacy and adverse effects in schizophrenia
10.1016/j.bbr.2020.113098 · 2021 · External reference
Prolactin and thyroid stimulating hormone (TSH) levels and sexual dysfunction in patients with schizophrenia treated with conventional antipsychotic medication: a cross-sectional study
10.12659/msm.913759 · 2018 · External reference
Efficacy and tolerability of seven antipsychotic drugs in acutely ill patients with schizophrenia: a randomized, multicenter, assessor-blinded trial
10.1176/appi.ajp.20250111 · 2026 · External reference
